AtaiBeckley: Breakthrough Therapy for TRD, Positive BPL-003 Data, End-of-Phase 2 Meeting Scheduled

• AtaiBeckley reports Q3 2025 financial results • BPL-003 granted Breakthrough Therapy designation for TRD • Positive Phase 2b OLE study data for BPL-003 in TRD • Positive Phase 2a data for BPL-003 induction regimen in TRD • Scheduled End-of-Phase 2 meeting with FDA for BPL-003 • Expect Phase 3 clinic guidance from FDA • AtaiBeckley solidifies position as global leader in transformative mental health therapies • BPL-003 nasal spray targets treatment-resistant depression • Data supports potential added and sustained antidepressant effects • Improved outcomes with two-dose induction regimen • Potential breakthrough therapy for TRD treatment • AtaiBeckley's BPL-003 demonstrates positive results in clinical trials • Strong position in global mental health therapies market